Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NDI-219216 in Advanced Solid Tumors
NCT06898450Phase 2Recruiting
- Sponsor
- Nimbus Therapeutics
- Start
- Mar 2025
- Primary completion
- Oct 2031
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, open-label trial of NDI-219216 in solid tumor (3 arms), sponsored by Nimbus Therapeutics. Primary endpoints: Dose Limiting Toxicities at 21 days, Adverse Events and Serious Adverse Events and 4 more. Started Mar 2025; status: recruiting.
02
Drugs
NDI-219216
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06898450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06898450.